Torlakovic EE - Search Results

1

A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma.

Torlakovic EE, Aamot HV, Heim S. Torlakovic EE, et al. J Pathol. 2006 Jun;209(2):258-64. doi: 10.1002/path.1981. J Pathol. 2006. PMID: 16583359

2

Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations.

Aamot HV, Torlakovic EE, Eide MB, Holte H, Heim S. Aamot HV, et al. Among authors: torlakovic ee. J Cancer Res Clin Oncol. 2007 Jul;133(7):455-70. doi: 10.1007/s00432-006-0188-3. Epub 2007 Jan 18. J Cancer Res Clin Oncol. 2007. PMID: 17235551

3

Prognostic significance of PU.1 in follicular lymphoma.

Torlakovic EE, Bilalovic N, Golouh R, Zidar A, Angel S. Torlakovic EE, et al. J Pathol. 2006 Jul;209(3):352-9. doi: 10.1002/path.1986. J Pathol. 2006. PMID: 16639693

4

PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.

Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J. Torlakovic E, et al. J Pathol. 2005 Jul;206(3):312-9. doi: 10.1002/path.1777. J Pathol. 2005. PMID: 15892171

5

Follicular pattern of bone marrow involvement by follicular lymphoma.

Torlakovic E, Torlakovic G, Brunning RD. Torlakovic E, et al. Am J Clin Pathol. 2002 Nov;118(5):780-6. doi: 10.1309/EG2M-YHB9-WEFW-7H1R. Am J Clin Pathol. 2002. PMID: 12428800

6

Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma.

Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D, Torlakovic E. Bilalovic N, et al. Am J Clin Pathol. 2004 Jan;121(1):34-42. doi: 10.1309/TNKL-7GDC-66R9-WPV5. Am J Clin Pathol. 2004. PMID: 14750238

7

Antibody selection in immunohistochemical detection of cyclin D1 in mantle cell lymphoma.

Torlakovic E, Nielsen S, Vyberg M. Torlakovic E, et al. Am J Clin Pathol. 2005 Nov;124(5):782-9. doi: 10.1309/TYE7-K2CQ-MQ70-7FRT. Am J Clin Pathol. 2005. PMID: 16203276

8

Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study.

Torlakovic EE, Naresh K, Kremer M, van der Walt J, Hyjek E, Porwit A. Torlakovic EE, et al. J Clin Pathol. 2009 Jun;62(6):547-51. doi: 10.1136/jcp.2008.063446. J Clin Pathol. 2009. PMID: 19474355

9

Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience.

Copete M, Garratt J, Gilks B, Pilavdzic D, Berendt R, Bigras G, Mitchell S, Lining LA, Cheung C, Torlakovic EE. Copete M, et al. Among authors: torlakovic ee. J Clin Pathol. 2011 Mar;64(3):220-5. doi: 10.1136/jcp.2010.085258. Epub 2011 Jan 22. J Clin Pathol. 2011. PMID: 21258091

10

Pax-5 expression in nonhematopoietic tissues.

Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA. Torlakovic E, et al. Am J Clin Pathol. 2006 Nov;126(5):798-804. doi: 10.1309/XEC7-JMW9-YRM7-4RNO. Am J Clin Pathol. 2006. PMID: 17050077

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page